phone image

Phone: 253-200-3166

Icon of a fax machine with a telephone receiver.

Fax: 253-200-3167

Woman and child picking strawberries in a field, both smiling, wearing white clothing.

What is Lutathera?

Lutathera (lutetium Lu 177 dotatate) is a radioligand therapy used to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including those affecting the pancreas and gastrointestinal tract. It is designed for patients whose tumors express somatostatin receptors (SSTRs) and have progressed despite other treatments.

How Lutathera Works

Lutathera contains Lutetium-177, a radioactive isotope, combined with a somatostatin analog that specifically binds to somatostatin receptors (SSTRs) found on neuroendocrine tumors. Once attached to tumor cells, Lutathera delivers localized beta radiation, which damages the DNA of the cancer cells, inhibiting their growth and progression. Because this therapy is highly targeted, it primarily affects tumor cells while minimizing damage to surrounding healthy tissues, reducing potential side effects.

Administration

  • Given as a slow intravenous (IV) infusion over 30-40 minutes

  • Administered every 8 weeks, for a total of four doses

  • Patients also receive amino acid infusions to help protect kidney function during treatment

Our healthcare team follows a comprehensive evaluation process to determine if Pluvicto is the appropriate treatment for you. This decision is based on several key factors, including your medical history, cancer progression, and overall health status.